Muscle Pathology in Dystrophic Rats and Zebrafish Is Unresponsive to Taurine Treatment, Compared to the <i>mdx</i> Mouse Model for Duchenne Muscular Dystrophy

Muscle Pathology in Dystrophic Rats and Zebrafish Is Unresponsive to Taurine Treatment, Compared to the <i>mdx</i> Mouse Model for Duchenne Muscular Dystrophy

Inflammation and oxidative stress are strongly implicated in the pathology of Duchenne muscular dystrophy (DMD), and the sulphur-containing amino acid taurine ameliorates both and decreases dystropathology in the <i>mdx</i> mouse model for DMD. We therefore further tested taurine as a th...

Full description

Bibliographic Details
Main Authors:	Jessica R. Terrill, Corinne Huchet, Caroline Le Guiner, Aude Lafoux, Dorian Caudal, Ankita Tulangekar, Robert J. Bryson-Richardson, Tamar E. Sztal, Miranda D. Grounds, Peter G. Arthur
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Metabolites
Subjects:	duchenne muscular dystrophy DMD<sup>mdx</sup> rat <i>dmd</i> zebrafish taurine therapies for DMD animal models for DMD
Online Access:	https://www.mdpi.com/2218-1989/13/2/232

Similar Items

Taurine and Methylprednisolone Administration at Close Proximity to the Onset of Muscle Degeneration Is Ineffective at Attenuating Force Loss in the Hind-Limb of 28 Days Mdx Mice
by: Robert G. Barker, et al.
Published: (2018-09-01)

The new challenge of “exercise + X″ therapy for Duchenne muscular dystrophy—Individualized identification of exercise tolerance and precise implementation of exercise intervention
by: Yuhui Su, et al.
Published: (2022-08-01)

Inflammation in Duchenne Muscular Dystrophy–Exploring the Role of Neutrophils in Muscle Damage and Regeneration
by: Ankita Tulangekar, et al.
Published: (2021-10-01)

Indicators of increased ER stress and UPR in aged D2-mdx and human dystrophic skeletal muscles
by: Swathy Krishna, et al.
Published: (2023-04-01)

CLINICAL CASE OF DUCHENNE MYODYSTROPHY
by: Elena Anatolyevna Tkachuk, et al.
Published: (2023-06-01)

DMD mutations in pediatric patients with phenotypes of Duchenne/Becker muscular dystrophy
by: Ge Liping, et al.
Published: (2024-11-01)

Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
by: Maxime RF Gosselin, et al.
Published: (2022-09-01)

Isolation and Characterization of Primary DMD Pig Muscle Cells as an <i>In Vitro</i> Model for Preclinical Research on Duchenne Muscular Dystrophy
by: Tina Donandt, et al.
Published: (2022-10-01)

Molecular characterization and reclassification of a 1.18 Mbp DMD duplication following positive carrier screening for Duchenne/Becker muscular dystrophy
by: Cinthya J. Zepeda‐Mendoza, et al.
Published: (2022-07-01)

Altered Synaptic Transmission and Excitability of Cerebellar Nuclear Neurons in a Mouse Model of Duchenne Muscular Dystrophy
by: Tabita Kreko-Pierce, et al.
Published: (2022-07-01)

Do Our Patients Really Need Telerehabilitation? Digital Physical Therapy for Boys with Duchenne Muscular Dystrophy in the COVID-19 Pandemic
by: Agnieszka Sobierajska-Rek, et al.
Published: (2022-05-01)

Accelerating the <i>Mdx</i> Heart Histo-Pathology through Physical Exercise
by: Jacopo Morroni, et al.
Published: (2021-07-01)

Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
by: Daniel Ebrahimi-Fakhari, et al.
Published: (2018-10-01)

Corrigendum: Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
by: Daniel Ebrahimi-Fakhari, et al.
Published: (2019-07-01)

Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
by: Aravindhan Veerapandiyan, et al.
Published: (2024-09-01)

Evaluation of cardiac functions in children with Duchenne Muscular Dystrophy: A prospective case-control study
by: Abdelrahim Abdrabou Sadek, et al.
Published: (2017-11-01)

Blind Source Separation Using Time-Delayed Dynamic Mode Decomposition
by: Gyurhan Nedzhibov
Published: (2025-02-01)

Estimating health state utilities in Duchenne muscular dystrophy using the health utilities index and EQ-5D-5L
by: Ivana F. Audhya, et al.
Published: (2023-12-01)

CD38‐NADase is a new major contributor to Duchenne muscular dystrophic phenotype
by: Antoine de Zélicourt, et al.
Published: (2022-03-01)

Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI)
by: Shelagh M. Szabo, et al.
Published: (2022-06-01)

DMD deletions underlining mild dystrophinopathies: literature review highlights phenotype-related mutation clusters and provides insights about genetic mechanisms and prognosis
by: Fernanda Fortunato, et al.
Published: (2024-01-01)

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
by: Shin'ichi Takeda, et al.
Published: (2013-06-01)

Dwarf Open Reading Frame (DWORF) Gene Therapy Ameliorated Duchenne Muscular Dystrophy Cardiomyopathy in Aged mdx Mice
by: Emily D. Morales, et al.
Published: (2023-02-01)

Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy
by: Claudia Brogna, et al.
Published: (2021-11-01)

Intellectual Ability in the Duchenne Muscular Dystrophy and Dystrophin Gene Mutation Location
by: Rasic Milic V., et al.
Published: (2014-12-01)

Mechanisms of Chimeric Cell Therapy in Duchenne Muscular Dystrophy
by: Maria Siemionow, et al.
Published: (2024-09-01)

Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis
by: Rita Spathis, et al.
Published: (2025-03-01)

Enhanced expression of dystrophin, IGF-1, CD44 and MYH3 in plasma and skeletal muscles including diaphragm of mdx mice after oral administration of Neu REFIX beta 1,3-1,6 glucan
by: Senthilkumar Preethy, et al.
Published: (2025-02-01)

A New Approach to Assess Quality of Motion in Functional Task of Upper Limb in Duchenne Muscular Dystrophy
by: Wiktoria Wojnicz, et al.
Published: (2022-11-01)

Genomic insights into Duchene muscular dystrophy: Analysis of 1250 patients reveals 30% novel genetic patterns and 6 novel variants
by: Khalda Amr, et al.
Published: (2024-12-01)

Patients Monitoring During Treatment With Injectable DMDs (INF and GA) (ORP-11)
by: Zahra Nikoo
Published: (2023-01-01)

The Interplay of Mitophagy and Inflammation in Duchenne Muscular Dystrophy
by: Andrea L. Reid, et al.
Published: (2021-07-01)

Experience of observing patients with Duchenne myopathy
by: L. I. Minaycheva, et al.
Published: (2023-12-01)

A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy
by: Chady H. Hakim, et al.
Published: (2017-09-01)

Age-Dependent Dysregulation of Muscle Vasculature and Blood Flow Recovery after Hindlimb Ischemia in the <i>mdx</i> Model of Duchenne Muscular Dystrophy
by: Paulina Podkalicka, et al.
Published: (2021-04-01)

A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy
by: Valeria Botti, et al.
Published: (2022-11-01)

Unique pattern of late gadolinium enhancement on cardiac magnetic resonance imaging in Duchenne muscular dystrophy
by: Madhusudan Ganigara, et al.
Published: (2016-01-01)

Calcium handling maturation and adaptation to increased substrate stiffness in human iPSC-derived cardiomyocytes: The impact of full-length dystrophin deficiency
by: Josè Manuel Pioner, et al.
Published: (2022-11-01)

Corrigendum: Calcium handling maturation and adaptation to increased substrate stiffness in human iPSC-derived cardiomyocytes: the impact of full-length dystrophin deficiency
by: Josè Manuel Pioner, et al.
Published: (2023-06-01)

Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy
by: Josè Manuel Pioner, et al.
Published: (2020-05-01)